Why ICU Medical is back on investors’ radar
ICU Medical (ICUI) has moved back into focus after resolving a longstanding FDA warning letter tied to its Smiths Medical business and posting fourth quarter results with adjusted earnings above analyst expectations, along with 2026 guidance that came in ahead of consensus.
The company paired these updates with detailed 2026 earnings guidance, giving investors clearer visibility into expected GAAP net income of US$26 million to US$44 million and GAAP earnings per share of US$1.03 to US$1.74.
See our latest analysis for ICU Medical.
The share price, which last closed at US$151.57, has had a 7 day share price return of 4.6% and a year to date share price return of 9.4%. In contrast, the 1 year total shareholder return of a 5.4% loss and 5 year total shareholder return of a 27% loss show that recent momentum follows a weaker long term picture as investors react to the FDA resolution, earnings beat and new 2026 guidance.
If ICU Medical’s recent move has you thinking about what else could be on your watchlist, this is a good moment to broaden your search with 27 healthcare AI stocks.
With ICU Medical trading at US$151.57, carrying an intrinsic value estimate that implies a 33% discount and sitting about 20% below analyst targets, you have to ask yourself: is this a genuine opportunity, or is the market already pricing in the recovery story?
Most Popular Narrative: 17% Undervalued
At $151.57, ICU Medical sits below a widely followed fair value estimate of about $182.67, putting attention on what needs to go right to close that gap.
Manufacturing network consolidations, portfolio optimization, and realization of integration synergies from the Smiths Medical acquisition are driving visible improvements in gross margin, while further benefits are expected once remaining plant transitions complete over the next year; sustained gross margin expansion supports higher profitability.
Want to see what is baked into that fair value? The narrative leans on a specific mix of revenue stability, margin uplift and richer earnings power. Curious which assumptions really move the model?
Result: Fair Value of $182.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if tariff costs bite harder than expected or if ongoing integration and regulatory work around Smiths Medical encounters setbacks.
Find out about the key risks to this ICU Medical narrative.
Next Steps
Unsure whether this story skews more toward risk or opportunity? Take a closer look at the underlying data today and weigh the mix of concerns and potential upsides for yourself with 4 key rewards and 3 important warning signs.
Looking for more investment ideas?
If this story has sharpened your thinking, do not stop here. Use the Simply Wall St screener to stack your watchlist with fresh, data driven ideas today.
- Target stability first by checking companies with resilient finances and low risk profiles through our 80 resilient stocks with low risk scores before market sentiment shifts again.
- Spot potential bargains early by scanning companies that combine quality with attractive pricing using our 56 high quality undervalued stocks, so you are not chasing moves later.
- Strengthen your income stream by reviewing stocks that feature reliable payouts and higher yields via our 15 dividend fortresses while those opportunities are still available.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com